A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 May 2018
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 25 Apr 2018 Planned End Date changed from 4 Apr 2019 to 28 May 2020.
- 25 Apr 2018 Planned primary completion date changed from 31 Jan 2019 to 4 Apr 2019.
- 03 Aug 2017 Planned End Date changed from 21 Mar 2019 to 4 Apr 2019.